Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Ganciclovir may ease some of the side effects of cancer treatment. Vaccines made
from a person's modified malignant mesothelioma cells may make the cancer more sensitive to
ganciclovir.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus ganciclovir in
treating patients who have stage I, stage II, or stage III malignant mesothelioma.
Phase:
Phase 1
Details
Lead Sponsor:
Louisiana State University Health Sciences Center in New Orleans